



ward
wizard

Innovations & Mobility Limited
(Formerly known as Manvijay
Development Co. Ltd.)
An ISO 9001 : 2015 Company

Date: 01st October, 2020

To,

BSE Limited

Listing Compliance

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai-400 001.

Ref: Wardwizard Innovations & Mobility Limited (Formerly known as Manvijay Development Company Limited) (Scrip Code – BSE 538970)

Sub: Compliance under Regulation 47 of Securities & Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 ["LODR"]

Dear Sir,


Pursuant to the Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed copies of Newspaper advertisement published in the Business Standard, English with all editions and Punya Nagari, Marathi with all Maharashtra editions on **September 30, 2020** for change of registered office of the company from "State of Maharashtra" to "State of Gujarat" as per Section 13 of the Companies Act, 2013.

Kindly take the same on record.

Thanking you,

For Wardwizard Innovations & Mobility Limited

(Formerly known as Manvijay Development Company Limited)


Jaya Ashok Bhardwaj

Compliance Officer/ Company Secretary



CIN NO. - L35100MH1982PLC264042

Registered office address - 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Rd, Girgaon, Mumbai- 400004(Maharashtra), India

Corporate Office - C-222, GIDC Makarpura Industrial Estate, Vadodara - 390010, Gujarat, India

Email id - compliance@wardwizard.in Website - www.wardwizard.in / www.manvijay.com Tel No. - +91 9727755083

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic. "Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L33102MH1982PLC26942

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai
in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

AND
in the matter of WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Milestone Residency Bhyeli, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of his/her objection(s) supported by an affidavit stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the application to the Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Yeshu Sarajay Gupsa Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc. etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2820TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KAUR	804160	53201	5216991-5216735	75
		183619	5216736-5216795	100
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	20		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkatarajasekar
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities/requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabestee@yahooin
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing Inspection, Packing and Delivery of Two Tonnage weather proof, L.F. PVC Cables, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 heating dry pressure extrusion process) of PVC compound of Type ST-1, for service voltage of 1.1 kV, dry 50°PM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C+0	12000
2	2C+3	2000

Start date for down loading of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for down loading of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender is not completed due to any reason, no contingency will be published in newspapers. Details regarding contingency may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MM, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,848.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,863.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L28197TN1987PLC02640
Regd. Office - 112, Appasaheb Street, Chennai - 600 001, Telephone No. +91 43 2324 4321
Secretary Office - 114, Sarabhai High Road, Mysore, Chennai - 600 004, Telephone No. +91 46 4302 3200 Fax No. +91 44 4302 3428
Website - www.shriramcityunionfinance.com e-mail - customer.support@shriramcityunionfinance.com Toll Free No. 1800204008

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by MIS Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makal Kurni" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,620
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

2. INTEREST RATES-ON FIXED DEPOSITS GREATER THAN Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.48	7.53	7.60	7.75	7.48	7.75	5,385
	24	7.67	7.72	7.80	7.95	7.67	8.27	5,625
	36	8.09	8.15	8.23	8.40	8.09	9.13	6,370
	48	8.13	8.19	8.27	8.45	8.13	9.58	6,915
	60	8.32	8.38	8.47	8.65	8.32	10.28	7,570
Applications through online mode Company's web site	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
	45	8.13	8.19	8.27	8.45	8.13	9.48	6,775

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic.

"Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L35102MH1982PLC28942

NOTICE
Form No. 25
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)

Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Milestone Residency Bhyai, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of his/her objections supported by an affidavit stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the application Company at its Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Yeshu Tarang Datta Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2826TN1987PLC068736
Regd. Office: Plot No.15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email id: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804166	53201	5216991-5216735	75
		183619	5216736-5216795	50
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	30		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkateshwaran
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing Inspection, Packing and Delivery of Two Tonnage weather proof, L.F. PVC Cable, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 heating dry pressure extrusion process of PVC compound of Type ST-1, for service voltage of 1.1 kV, duly GSPGM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C+0	12000
2	2C+3	2000

Start date for open bidding of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for open bidding of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender notice is not complied due to any reason, no contention will be published in newspapers. Details regarding contention may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MD, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,848.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,663.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L28197TN1980PLC02640
Regd. Office - 112, Appappa Reddy Street, Chennai - 600 001, Telephone No. +91 43 2324 4321
Secretary Office - 114, Sarathnagar High Road, Mysore, Chennai - 600 094, Telephone No. +91 46 4302 3300 Fax No. +91 44 4302 3428
Website: www.shriramcityunion.com e-mail: customer.support@shriramcityunion.com Toll Free No. 1800204008

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by MIS Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makkal Kural" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,600
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

2. INTEREST RATES-ON FIXED DEPOSITS GREATER THAN Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.48	7.53	7.60	7.75	7.48	7.75	5,385
	24	7.67	7.72	7.80	7.95	7.67	8.27	5,625
	36	8.09	8.15	8.23	8.40	8.09	9.13	6,370
	48	8.13	8.19	8.27	8.45	8.13	9.58	6,915
	60	8.32	8.38	8.47	8.65	8.32	10.28	7,570
Applications through online mode Company's web site	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
	45	8.13	8.19	8.27	8.45	8.13	9.48	6,775

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic. "Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L31102MH1982PLC294042

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Milestone Residency Bhyeli, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of his/her objections supported by an affidavit stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the applicant Company at its Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Yeshu Tarang Datta Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc. etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2820TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804160	53201	5216991-5216735	75
		183619	5216736-5216795	100
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	20		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkateshwaran
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing Inspection, Packing and Delivery of Two Tonnage weather proof, L.F. PVC Coated, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 healthy dry pressure extrusion process) of PVC compound of Type ST-1, for service voltage of 1.1 kV, duly GSPQM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C40	12000
2	2C43	2000

Start date for down loading of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for down loading of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender is not completed due to any reason, no contingency will be published in newspapers. Details regarding contingency may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/PM, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,348.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,663.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10/- each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L65917TN1980PLC02640
Regd. Office - 112, Appasaheb Street, Chennai - 600 001, Telephone No. +91 43 3234 4321
Secretary Office - 114, Sarabhai High Road, Mysore, Chennai - 600 094, Telephone No. +91 43 4302 3300 Fax No. +91 44 4302 3428
Website: www.shriramcityunionfinance.com e-mail: customer.support@shriramcityunionfinance.com Toll Free No. 1800204008

MONEY WHEN YOU NEED IT MOST

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by MIS Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makal Kurni" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,600
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

2. INTEREST RATES-ON FIXED DEPOSITS GREATER THAN Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.48	7.53	7.60	7.75	7.48	7.75	5,385
	24	7.67	7.72	7.80	7.95	7.67	8.27	5,625
	36	8.09	8.15	8.23	8.40	8.09	9.13	6,370
	48	8.13	8.19	8.27	8.45	8.13	9.58	6,915
	60	8.32	8.38	8.47	8.65	8.32	10.28	7,570
Applications through online mode Company's web site	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
	45	8.13	8.19	8.27	8.45	8.13	9.48	6,775

Additional Interest (for table 1 and 2 above) : 0

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic. "Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L31020MH1982PLC294042

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 16th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Milestone Residency Bhyeli, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of his/her objections supported by an affidavit stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the applicant Company at its Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Yeshu Sarajay Gupda Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L28206TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email id: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804166	53201	5216991-5216735	75
		183619	5216736-5216795	50
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	20		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkatarajasekar
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing, Installation, Packing and Delivery of Two Tens Core, weather proof, L5, PVC Coated, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 healthy dry pressure extrusion process of PVC compound of Type ST-1, for service voltage of 1.1 kV, dly GSPGM Marked as per IS: 5942:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C40	12000
2	2C43	2000

Start date for down loading of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for down loading of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender is not completed due to any reason, no contingency will be published in newspapers. Details regarding contingency may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MM, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,848.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,863.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L28197TN1987PLC02640
Regd. Office - 112, Annapurna Madhav Street, Chennai - 600 091, Telephone No. +91 44 3234 4431
Secretary Office - 114, Sarathnagar High Road, Mysore, Chennai - 600 094, Telephone No. +91 44 4302 3300 Fax No. +91 44 4302 3428
Website: www.shriramcityunionfinance.com e-mail: customer.support@shriramcityunionfinance.com Toll Free No. 1800204088

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by M/S Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makkal Kural" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,620
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

2. INTEREST RATES-ON FIXED DEPOSITS GREATER THAN Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.48	7.53	7.60	7.75	7.48	7.75	5,385
	24	7.67	7.72	7.80	7.95	7.67	8.27	5,625
	36	8.09	8.15	8.23	8.40	8.09	9.13	6,370
	48	8.13	8.19	8.27	8.45	8.13	9.58	6,915
	60	8.32	8.38	8.47	8.65	8.32	10.28	7,570
Applications through online mode Company's web site	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
	45	8.13	8.19	8.27	8.45	8.13	9.48	6,775

Additional Interest (for table 1 and 2 above) : 0.40% p.a. will

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic. "Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year. Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L33102MH1982PLC28942

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Milestone Residency Bhyai, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of his/her objection(s) supported by an affidavit stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the application to the Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Marvjay Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Yeshu Tarang Gupta
Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc. etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2826TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804160	53201	5216991-5216735	75
		183619	5216736-5216795	50
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	25		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkateshwaran
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing, Installation, Packing and Delivery of Two Tonnage weather proof, L.F. PVC Cable, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 healthy dry pressure extrusion process) of PVC compound of Type ST-1, for service voltage of 1.1 kV, dry 50%PM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C40	12000
2	2C40	2000

Start date for open bidding of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for open bidding of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed Bidding & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender is not completed due to any reason, no refund will be published in newspapers. Details regarding refund may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MM, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,348.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,863.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L28197TN1987PLC02640
Regd. Office - 112, Anna Nagar Street, Chennai - 600 092, Telephone No. +91 43 3234 4321
Branch Office - 114, Sarathai High Road, Mysore, Chennai - 600 094, Telephone No. +91 46 4302 3300 Fax No. +91 44 4302 3428
Website: www.shriramcityunion.com e-mail: customer.support@shriramcityunion.com Toll Free No. 1800204088

MONEY WHEN YOU NEED IT MOST

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by M/S Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makkal Kural" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,620
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

2. INTEREST RATES-ON FIXED DEPOSITS GREATER THAN Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.48	7.53	7.60	7.75	7.48	7.75	5,385
	24	7.67	7.72	7.80	7.95	7.67	8.27	5,625
	36	8.09	8.15	8.23	8.40	8.09	9.13	6,370
	48	8.13	8.19	8.27	8.45	8.13	9.58	6,915
	60	8.32	8.38	8.47	8.65	8.32	10.28	7,570
Applications through online mode Company's web site	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
	45	8.13	8.19	8.27	8.45	8.13	9.48	6,775

Additional Interest (for table 1 and 2 above) : 0.40% p.a. will be paid for Senior citizen (completed age 60 years on the date of deposit/renewal), 0.25% p.a. will be paid

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic.

"Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L31020MH1982PLC294042

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Milestone Residency Bhyai, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of higher order (supported by an affidavit) stating the nature of his/her interest and grounds of opposition to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the applicant Company at its Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Years Sarvagya Gupta Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc. etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2826TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email id: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804160	53201	5216991-5216735	75
		183619	5216736-5216795	50
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	20		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkateshwaran
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing Inspection, Packing and Delivery of Two Tonnage weather proof, L3, PVC Coated, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 healthy dry pressure extrusion process of PVC compound of Type ST-1, for service voltage of 1.1 kV, dly GSPGM Marked as per IS: 5942:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (Mtr)
1	2C40	12000
2	2C40	2000

Start date for down loading of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for down loading of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender file is not completed due to any reason, no contention will be published in newspapers. Details regarding contention may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MM, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,348.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,863.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L65917TN1980PLC02640
Regd. Office - 112, Annapurna Mall, Chennai - 600 019, Telephone No. +91 43 3234 4321
Secretary Office - 114, Sarathnagar High Road, Mysore, Chennai - 600 094, Telephone No. +91 43 4302 3200 Fax No. +91 44 4302 3428
Website: www.shriramcityunion.com e-mail: customer.support@shriramcityunion.com Toll Free No. 1800204008

MONEY WHEN YOU NEED IT MOST

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by M/S Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makkal Kural" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,620
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

Additional Interest (for table 1 and 2 above) : 0.40% p.a. will be paid for Senior citizen (completed age 60 years on the date of deposit/renewal), 0.25% p.a. will be paid on all renewals of matured deposit of the Company. 0.15% p.a. will be paid to employees of Shriram Group Companies and their relatives.

All application forms for fixed deposits of the Company shall contain the above rates of interest in addition to other terms and conditions which may be referred to before investing in the Company's Fixed Deposit.

For SHRIRAM CITY UNION FINANCE LIMITED,
Sd
R Chandrasekar
Chief Financial Officer

Place : Chennai
Date : 30-09-2020

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic.

"Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L35102MH1982PLC28942

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Hilestone Residency Bhyai, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of his/her objections supported by an affidavit stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the application to the Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Yeshu Sarang Datta Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc etc.
- Only machinery & shed approx weight 2000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2826TN1987PLC068736
Regd. Office: Plot No.15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email id: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804160	53201	5216991-5216735	75
		183619	5216736-5216795	100
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	20		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkatarajasekar
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): U40109PB2010SGCC33813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing, Installation, Packing and Delivery of Two Tonnage weather proof, L.F. PVC Cables, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 healthy dry pressure extrusion process of PVC compound of Type ST-1, for service voltage of 1.1 kV, dry EPDM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C40	12000
2	2C43	2000

Start date for down loading of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for down loading of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender is not completed due to any reason, no contingency will be published in newspapers. Details regarding contingency may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MM, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.84	7,240.52	13,703.50	16,800.27	69,984.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,848.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.89)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,863.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L28197TN1989PLC02640
Regd. Office - 112, Appappa Reddy Street, Chennai - 600 001, Telephone No. +91 43 2324 4321
Secretary Office - 114, Sarathnagar High Road, Mysore, Chennai - 600 094, Telephone No. +91 46 4302 3300 Fax No. +91 44 4302 3428
Website - www.shriramcityunionfinance.com e-mail - customer.support@shriramcityunionfinance.com Toll Free No. 1800204008

MONEY WHEN YOU NEED IT MOST

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by MIS Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makkal Kural" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,920
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

Additional Interest (for table 1 and 2 above) : 0.40% p.a. will be paid for Senior citizen (completed age 60 years on the date of deposit/renewal), 0.25% p.a. will be paid on all renewals of matured deposit of the Company. 0.15% p.a. will be paid to employees of Shriram Group Companies and their relatives.

All application forms for fixed deposits of the Company shall contain the above rates of interest in addition to other terms and conditions which may be referred to before investing in the Company's Fixed Deposit.

For SHRIRAM CITY UNION FINANCE LIMITED,
Sd
R Chandrasekar
Chief Financial Officer

Place : Chennai
Date : 30-09-2020

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic. "Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L33102MH1982PLC294042

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)

Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaon, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaon, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Hiteshore Residency Bhoyl, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of higher order (supported by an affidavit) stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the applicant Company at its Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaon, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Years Sarvagya Gupta
Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- 1) Installed capacity of TMT units is 1,10,000MT per annum.
- 2) 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc. etc.
- 3) Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- 4) The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2820TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambatur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804160	53201	5216991-5216735	75
		183619	5216736-5216795	50
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	20		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkateshwaran
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

1. The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
2. Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
3. This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad

Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN) : L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing Inspection, Packing and Delivery of Two Tonnage weather proof, L.F. PVC Cable, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 heating dry pressure extrusion process) of PVC compound of Type ST-1, for service voltage of 1.1 kV, dly GSPGM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C40	12000
2	2C40	2000

Start date for down loading of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for down loading of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender process is not completed due to any reason, no contingency will be published in newspapers. Details regarding contingency may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/PM, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,348.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,067.63)	(1,387.23)	(29,183.82)	6,819.19	(27,863.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

1. The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
2. Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
3. The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L28197TN1987PLC02640
Regd. Office - 112, Appasaheb Street, Chennai - 600 001, Telephone No. +91 43 2324 4321
Secretary Office - 114, Sarabhai High Road, Mysore, Chennai - 600 094, Telephone No. +91 46 4302 3300 Fax No. +91 44 4302 3428
Website - www.shriramcityunionfinance.com e-mail - customer.support@shriramcityunionfinance.com Toll Free No. 1800204008

MONEY WHEN YOU NEED IT MOST

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by MIS Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makkal Kural" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,620
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

2. INTEREST RATES-ON FIXED DEPOSITS GREATER THAN Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.48	7.53	7.60	7.75	7.48	7.75	5,385
	24	7.67	7.72	7.80	7.95	7.67	8.27	5,625
	36	8.09	8.15	8.23	8.40	8.09	9.13	6,370
	48	8.13	8.19	8.27	8.45	8.13	9.58	6,915
	60	8.32	8.38	8.47	8.65	8.32	10.28	7,570
Applications through online mode Company's web site	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
	45	8.13	8.19	8.27	8.4			

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic.

"Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L33102MH1982PLC26942

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Milestone Residency Bhyeli, Vadodra-391415, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of his/her objections supported by an affidavit stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the applicant Company at its Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Years Sarvagya Gupta
Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc. etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2826TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804166	53201	5216991-5216735	75
		183619	5216736-5216795	50
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	20		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkateshwaran
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing Inspection, Packing and Delivery of Two Tonnage weather proof, L.F. PVC Cable, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 heating dry pressure extrusion process) of PVC compound of Type ST-1, for service voltage of 1.1 kV, dly GSPGM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C+0	12000
2	2C+3	2000

Start date for open bidding of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for open bidding of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender is not completed due to any reason, no contingency will be published in newspapers. Details regarding contingency may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MM, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,848.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,663.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L65917TN1980PLC012640
Regd. Office - 112, Annapurna Indira Street, Chennai - 600 031, Telephone No. +91 44 3234 4431
Secretary Office - 114, Sarabjee High Road, Mysore, Chennai - 600 094, Telephone No. +91 44 4202 3200 Fax No. +91 44 4202 3428
Website: www.shriramcityunionfinance.com e-mail: customer.support@shriramcityunionfinance.com Toll Free No. 1800204008

MONEY WHEN YOU NEED IT MOST

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by MIS Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makkal Kural" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,620
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

2. INTEREST RATES-ON FIXED DEPOSITS GREATER THAN Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.48	7.53	7.60	7.75	7.48	7.75	5,385
	24	7.67	7.72	7.80	7.95	7.67	8.27	5,625
	36	8.09	8.15	8.23	8.40	8.09	9.13	6,370
	48	8.13	8.19	8.27	8.45	8.13	9.58	6,915
	60	8.32	8.38	8.47	8.65	8.32	10.28	7,570
Applications through online mode Company's web site	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
	45	8.13	8.19	8.27	8.45	8.13	9.48	6,77

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic.

"Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L35102MH1982PLC294042

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, near to Milestone Residency Bhyeli, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of higher order (supported by an affidavit) stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the applicant Company at its Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Yeshu Sarajay Gupsa Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc. etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L28206TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804160	53201	5216991-5216735	75
		183619	5216736-5216795	50
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	20		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkateshwaran
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum, Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN) : L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabestee@yahooin
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing Inspection, Packing and Delivery of Two Tonnage weather proof, L.F. PVC Cables, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 healthy dry pressure extrusion process) of PVC compound of Type ST-1, for service voltage of 1.1 kV, duly GSPGM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C40	12000
2	2C40	2000

Start date for open bidding of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for open bidding of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender is not completed due to any reason, no contingency will be published in newspapers. Details regarding contingency may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MM, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,348.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,863.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10/- each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L28197TN1987PLC02640
Regd. Office - 112, Appasaheb Street, Chennai - 600 001, Telephone No. +91 43 3234 4321
Secretary Office - 114, Sarabhai High Road, Mysore, Chennai - 600 094, Telephone No. +91 43 4302 3300 Fax No. +91 44 4302 3428
Website - www.shriramcityunionfinance.com e-mail - customer.support@shriramcityunionfinance.com Toll Free No. 1800204008

MONEY WHEN YOU NEED IT MOST

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by M/S Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makkal Kural" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,620
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

Additional Interest (for table 1 and 2 above) : 0.40% p.a. will be paid for Senior citizen (completed age 60 years on the date of deposit/renewal), 0.25% p.a. will be paid on all renewals of matured deposit of the Company. 0.15% p.a. will be paid to employees of Shriram Group Companies and their relatives.

All application forms for fixed deposits of the Company shall contain the above rates of interest in addition to other terms and conditions which may be referred to before investing in the Company's Fixed Deposit.

For SHRIRAM CITY UNION FINANCE LIMITED,
Sd/-
R Chandrasekar
Chief Financial Officer

Place : Chennai
Date : 30-09-2020

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic.

"Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L33102MH1982PLC294042

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Hiteshore Residency Bhyeli, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of his/her objections supported by an affidavit stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the applicant Company at its Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Years Sarvagya Gupta
Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc. etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2820TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALR	804160	53201	5216991-5216735	75
		183619	5216736-5216795	50
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	30		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkateshwaran
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing Inspection, Packing and Delivery of Two Tens Core weather proof L3 PVC Cables with H2 Grade Aluminium Conductor insulated with Type IX PVC compound having 5 heating dry pressure extrusion process of PVC compound of Type ST-1 for service voltage of 1.1 kV, dry ESPGM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C+0	12000
2	2C+3	2000

Start date for down loading of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for down loading of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender is not completed due to any reason, no contingency will be published in newspapers. Details regarding contingency may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MD, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,848.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,067.63)	(1,387.23)	(29,183.82)	6,819.19	(27,863.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L65917TN1989PLC02640
Regd. Office - 112, Annapurna Indus. Estate, Chennai - 600 091, Telephone No. +91 43 3234 4321
Branch Office - 114, Sarathnagar High Road, Mysore, Chennai - 600 094, Telephone No. +91 43 4302 3200 Fax No. +91 43 4302 3428
Website: www.shriramcityunionfinance.com e-mail: customer.support@shriramcityunionfinance.com Toll Free No. 1800204008

MONEY WHEN YOU NEED IT MOST

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by MIS Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makkal Kural" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,600
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

2. INTEREST RATES-ON FIXED DEPOSITS GREATER THAN Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.48	7.53	7.60	7.75	7.48	7.75	5,385
	24	7.67	7.72	7.80	7.95	7.67	8.27	5,625
	36	8.09	8.15	8.23	8.40	8.09	9.13	6,370
	48	8.13	8.19	8.27	8.45	8.13	9.58	6,915
	60	8.32	8.38	8.47	8.65	8.32	10.28	7,570
Applications through online mode Company's web site	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
	45	8.13	8.19	8.27	8.45			

Serum to produce another 100 million Covid vaccine doses

Gets additional \$150-mn risk funding from Gates foundation

SOHINI DAS
Mumbai, 29 September



"IT IS IMPORTANT FOR GOVERNMENTS, GLOBAL HEALTH AND FINANCIAL INSTITUTIONS IN THE PUBLIC AND PRIVATE SECTOR TO COME TOGETHER IN ENSURING THAT NO ONE IS LEFT BEHIND IN THE ROAD TO RECOVERY..."

ADAR POONWALLA,
CEO, Serum Institute of India

Pune-based Serum Institute of India (SII), the world's largest vaccine maker by volume, will now be producing an additional 100 million Covid-19 vaccine doses for India as well as low- and medium-income countries (LMICs) in 2021. The vaccine will come for \$3 or around ₹250 per dose.

This would take the total volume of vaccines that SII will offer at this price to 200 million. The company has received an additional \$150 million risk funding from the Bill and Melinda Gates Foundation. The announcement practically takes forward the collaboration among SII, Gavi, the Vaccine Alliance and Bill and Melinda Gates Foundation. This comes after the August announcement when SII said it would deliver 100 million doses at ₹250 a dose. The partnership has now been extended to 200 million doses of Covid-19 vaccines, with AstraZeneca's as well as Novavax's vaccine being the candidates.

The Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further \$150 million to Gavi, bringing the total funding provided through this collaboration to \$300 million.

This is a part of the Gavi-Covax advance market commitment, a mechanism within the Covax facility. The Covax facility is a Gavi-coordinated pooled procurement mechanism for new Covid vaccines. Through this, Covax will ensure equitable access to vaccines for

each participating economy, using an allocation framework currently being formulated by the World Health Organization (WHO). The Gavi Covax commitment, which is currently seeking around \$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine.

The Gavi board has agreed upon the final list of 92 countries that will be supported by the Gavi Covax commitment. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi Covax commitment. The arrangement again provides an option to secure addi-

tional doses, if required. The collaboration will provide upfront capital to SII so that it can scale up its capacity. Once the vaccine candidates gain regulatory approval as well as WHO prequalification, the doses can be distributed as early as the first half of 2021.

Adar Poonwalla, CEO of SII, who recently tweeted his concern whether the Centre had ₹80,000 crore available with it over the next one year to distribute vaccine to Indians, said it will now manufacture and deliver up to an additional 100 million doses of Covid vaccine to India and LMICs in 2021.

He said, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest part of the world, providing full immunisation coverage."

Reiterating what Poonwalla felt, Seth Berkeley, CEO of Gavi said, "Last week, we were able to announce the historic number of countries that are now signed up for the Covax facility. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines. The collaboration brings us another step closer to achieving this goal." So far, 73 high-income economies have formally committed to joining the facility. In addition to the 92 low- and middle-income economies that are eligible for support from the Gavi Covax commitment.

Liquid remdesivir to smoothen supply

SOHINI DAS
Mumbai, 29 September

Shortage of key drug remdesivir, used to treat hospitalised Covid-19 patients, may ease as the liquid form of the medicine may make its way into the market soon. Makers here say that the innovator — Gilead — has come up with a liquid formulation that would be available in the market.

The liquid form may be easier and faster to manufacture. Currently, dry powder form of the drug is available and is converted to a solution. It is then injected into a patient. Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process and thus help ramp up supplies at a faster clip.

Said one manufacturer, "The manufacturing process for remdesivir is quite complex and it takes a minimum of 21 days to make the drug. Before one starts a batch, he has to make arrangements in the supply chain for the active ingredient, among others. So, it's a minimum one month before a batch is ready for the market."

He added, "Gilead has come up with a liquid form of remdesivir that would

FAR FROM OVER

- September saw a demand-supply mismatch for remdesivir as cases spiked
- Maharashtra, especially Mumbai hospitals, faced a crisis
- Companies ramped up production; Cipla doubled supplies
- Industry says a liquid form of remdesivir is

- expected soon
- This would simplify the manufacturing process and make it faster to produce
- Currently, manufacturing of remdesivir requires freeze-drying
- Pharma firms typically outsource this process



basically skip the process of lyophilisation and this can shorten the manufacturing process a bit. Moreover, there is only a limited capacity for lyophilisation in India."

Lyophilisation or cryodesiccation — or freeze drying as it is commonly known as — is a process of low temperature dehydration that involves freezing the product, lowering pressure and then removing ice by sublimation. This is in contrast to dehydration which involves evaporation of water by using heat.

Of the remdesivir makers in India,

Ahmedabad-based Cadila Healthcare (Zydus Cadila) has an in-house lyophilisation capacity.

A company source said that it is already making around 500,000 doses of the drug every month. One patient typically needs six doses. One manufacturer noted that in liquid form remdesivir would require cold chain for distribution.

Cipla has already doubled its remdesivir manufacturing capacity. A company spokesperson said, "We have ramped up production by leveraging multiple

sites. Supplies are up to date. We have ramped up our supplies by two times per month and this will help us fulfill requirements for areas with increased demand." Even on tocilizumab or actemra, which Cipla sells under a licensing agreement with Roche, the firm said it is actively collaborating with Roche to ensure sufficient supplies.

Hyderabad-based Hetero said it has already delivered 1.2 million doses of remdesivir which took care of 200,000 patients. "We have been continuously manufacturing the product and meeting the required demand. However, with a sudden spurt in the number of cases, we are also augmenting our capacities in order to meet the additional demand," said a company spokesperson.

He added that the supply chain, too, is sorted and there are no order backlogs in the Mumbai region. Hetero sells both dry powder and solution form of remdesivir.

Mumbai is probably facing the worst shortage of remdesivir at the moment with the city's largest dedicated Covid hospital — the Seven Hills Hospital — now languishing with less than 20 vials of the drug. It currently is treating around 1,100 patients.

Pharma firms inject urgency into exports

ANEESH PHADNIS
Mumbai, 29 September

Exports are helping pharmaceutical (pharma) companies sustain the growth momentum as they launch new products and tap newer markets.

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

"Exports to South Africa and the UK (which are the No. 2 and No. 3 markets for Indian pharma) have recovered after a decline in 2019-20. Exports to the US are growing steadily. Indian companies are also tapping new opportunities in Latin America. Earlier in the month, we signed an agreement with the state of Hidalgo in Mexico to promote exports and investment in that country. Mexico is

still a small market for us, but was the fastest growing export destination in the April-July period. Currently, the country largely depends on the US and Europe for its medicines. Indian companies are looking to grow their share by supplying antibiotics, antivirals, and chronic therapy drugs," said Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (PharmexCIL).

During April-July, drug-makers exported products worth \$7.4 billion — a growth of 9.5 per cent year-on-year (YoY). While the export of formulations and biologicals rose 16.7 per cent, the export of bulk drugs and intermediates fell 7.2 per cent. Vaccine exports, too, were lower by 19 per cent YoY as immunisation programmes took a back seat due to the

BOOSTER SHOT

- Exports rose 9.5% to \$7.4 bn in the April-July period
- Exports to the US (which accounts for 35% of total) grew 14%. The UK and South Africa business revived during the period
- Russia showed 5.6% decline because of subdued business and currency depreciation
- CRISIL expects higher exports to offset decline in domestic sales

Covid-19 pandemic. "Our key markets — the US and South Africa — are driving growth for us. We have had meaningful launches like the first generic version of Albuterol (bronchodilator) in

April and have a strong product pipeline in the US, especially in the respiratory segment. With fewer elective surgeries, we have been able to grow fast in both the markets because of new products and commercial excellence," said Kedar Upadhye, global chief financial officer, Cipla.

Drugmaker Lupin expects its exports to stabilise to pre-Covid levels in the next two quarters, with the launch of new products in Europe and the US. These include biosimilar Etanercept in Europe and Albuterol in the US.

The company has also reintroduced key anti-diabetic drugs like Glumetza and Fortamet in the US, following a voluntary recall earlier this year.

Rating agency CRISIL expects Indian pharma exports to grow at 11-12 per cent in the cur-

rent financial year and outpace the domestic market, which is estimated to grow 5-6 per cent. This would result in 8-9 per cent overall growth for the industry.

According to CRISIL, growth in exports to regulated markets like the US and Europe will be supported by a steady increase in new product launches from compliant plants, lower pricing pressure on existing generics, and a visible easing in scrutiny by the US Food and Drug Administration in recent months.

Tanvi Shah, associate director, CRISIL Ratings, said, "Higher exports should offset some of the reduction in domestic formulation sales because of pandemic-led disruptions, especially in the acute therapies segment (around 60 per cent of domestic formulation sales)."

WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as Marvjay Development Company Limited)
CIN : L35102MH1982PLC28942

NOTICE
Form No. 26
(Pursuant to Rule 30 of the Companies (Incorporation) Rules, 2014)
Advertisement to be published in the Newspaper for change of Registered Office of the Company from one State to another State.

Before the Central Government, Regional Director, Western Region, Ministry of Corporate Affairs, Maharashtra-Mumbai in the matter of the Companies Act, 2013, Section 13(4) of Companies Act, 2013 and Rule 30 of the Companies (Incorporation) Rules, 2014

IN THE MATTER OF WARDWARD INNOVATIONS & MOBILITY LIMITED (Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED) having its Registered Office at 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, Maharashtra, India

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation for alteration of the Memorandum of Association of the Company in terms of the special resolution passed by the Members through Postal Ballot dated 18th April, 2020 to enable the Company to change its Registered Office from 701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai-400004, in the State of Maharashtra to 1st Floor Hall No. 2 WR ICDN, next to Milestone Residency Bhyai, Vadodra-391419, in the State of Gujarat.

Any person whose interest is likely to be affected by the proposed change of the Registered Office of the Company may deliver or cause to be delivered or send by Registered post of higher order (supported by an affidavit) stating the nature of his/her interest and grounds of objection to the Central Government, Regional Director at Everest, 6th Floor, 100, Marine Drive, Mumbai, within 14 days (Fourteen days) from the date of publication of this Notice with a copy of the application to the Registered Office at the address mentioned below:

Regd. Office	Corp. Office
701, 7th Floor, Plot - 96/98, Platinum Arcade, JSS Rd, Central Plaza Cinema, Charni Road, Girgaum, Mumbai - 400004.	C-222, GDC, Maropada Industrial Estate, Vadodra - 390011, Gujarat.

For and on behalf of the Applicant
WARDWARD INNOVATIONS & MOBILITY LIMITED
(Formerly known as MARVJAY DEVELOPMENT COMPANY LIMITED)
50-Yeshu Sarajay Ganga Managing Director
DIN: 07811930

Place : Mumbai
Date : 28.09.20

SALE NOTICE
USED/ OLD ROLLING MILL/ TMT Manufacturing Plant & Machinery at Gummidipoondi for SALE

- Installed capacity of TMT units is 1,10,000MT per annum.
- 18inch - 3 stands, 14inch - 4 stands, 12inch - 2 stands, continuous DC Drive - 4 stands, flying shearing, automatic cooling bed with W channel 60Mtrs, gasifier plant, 2 hot billet shearing, 9 ladle machines etc. etc.
- Only machinery & shed approx weight 20000MT (TC) is available for Sale.
- The machinery can be re-installed for production.

Contact Sanjiv Narula: 88606 22712, 87663 36448.

ESAB INDIA LIMITED
CIN: L2826TN1987PLC068736
Regd. Office: Plot No. 15, 3rd Main Road, Industrial Estate, Ambattur, Chennai 600 056.
Telephone No: 044-4226 1100 | Email: investor.relations@esab.co.in

NOTICE is hereby given that the following share certificates issued by the company are stated to have been lost or misplaced or stolen and the registered holders of the shares have applied to the company for issue of duplicate share certificates:

Name of the Shareholder	Folio No.	Certificate No.	Definitive No.	Shares
SHYAMDAR SINGH AMARJIT KALIR	804160	53201	5216991-5216735	75
		183619	5216736-5216795	50
		183620	5216796-5216810	25
		183621	5216811-5216835	25
183622	5216836-5216865	30		

The public are hereby warned against purchase or dealing in any way with the above said share certificates. Any person(s) who has / have any claim(s) in respect of the said share certificates should lodge such claim(s) with the company at its registered office at the address given above within 15 days of the publication of the notice after which no claim will be entertained and the company will proceed to issue the duplicate share certificate(s).

Place : Chennai
Date : 30 September, 2020

For ESAB India Limited
S. Venkateshwaran
Company Secretary

TRANSSTROY (INDIA) LIMITED (UNDER LIQUIDATION)
PUBLIC NOTICE FOR E-AUCTION FOR SALE OF PLANT & MACHINERY

The Liquidator of Transstroy India Limited ("TIL"), appointed by the Hon'ble NCLT, Principal Bench, vide order dated 15.09.2019 hereby issues a public notice for the E-Auction for the sale of following plant & machinery of TIL on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" and "NO RECOURSE BASIS".

The Sale will be done by the Liquidator through the E-Auction platform of iqipoo at www.iqipoo.com

S.No.	Location	Details of asset
1	Tindivanam, Tiruchy and Dindigul (Tamil Nadu)	Used Highway Construction Plant and Equipment
2	Keknada (Andhra Pradesh)	Used Highway Construction Plant and Equipment
2	Betal (Madhya Pradesh)	Used Highway Construction Plant and Equipment

DETAILS FOR E-AUCTION:

- The E-Auction will be held on 15.10.2020 10:30 AM to 06:30 PM.
- Interested parties are requested to contact Mr. Hari Kumar on 9944366165/7702347777 (harikumar2@iqipoo.com), basis which other formalities requirements shall be duly taken care of.
- This Sale Notice shall be read with the Complete E-Auction Process Memorandum. Containing details of the Assets, eligibility, EMD etc which is available at <http://www.transstroyindia.com/home.html>

Date: 30.09.2020
Place: Hyderabad
Sd/- Dr. G.V.Narasimha Rao
Liquidator for Transstroy (India) Limited

PSPCL Punjab State Power Corporation Limited
Regd Office: PSEB Head Office, The Mall, Patiala-147001
Corporate Identification Number (CIN): L40109PB2010SGC033813
Phone No. 0175-2213047, Fax No. 0175-2225024
Mob: 098461-82844, 098461-11035 e-mail: pccabnsteel@yahoo.in
e-tendering page: www.aproc.punjab.gov.in

TENDER NOTICE
Design, Manufacture, Testing, Installation, Packing and Delivery of Two Tonnage weather proof, L.F. PVC Cables, with H2 Grade Aluminium Conductor, insulated with Type IX PVC compound, having 5 heating dry pressure extrusion process of PVC compound of Type ST-1, for service voltage of 1.1 kV, dry 50°PM Marked as per IS: 6842:2015 with latest approved specifications if any and as per PSPCL specification No. GG-1504 of following size & quantity:-

S.No.	Size(mm2)	Quantity (M)
1	2C+0	12000
2	2C+3	2000

Start date for down loading of documents from: 30 September 2020
www.aproc.punjab.gov.in

Last date for down loading of documents from: 03 November 2020 (upto 11:00 AM)
www.aproc.punjab.gov.in

Last date for Bid Submission: 03 November 2020 (upto 11:00 AM)

End of Opening date: 03 November 2020 (upto 11:00 AM)

For detailed HT & Tender specification please refer to www.aproc.punjab.gov.in
Note: It is informed that in case tender is not completed due to any reason, no contingency will be published in newspapers. Details regarding contingency may be seen on official PSPCL website www.pspcl.in

It will be published in Chief Purchase Officer/MD, Central Purchase Organisation, PSPCL, Patiala.

C312-2020 883468

A2Z INFRA ENGINEERING LTD.
CIN: L74999HR2002PLC034806
Registered Office: O-116, 1st Floor, DLF Shopping Mall, Arjun Marg, DLF Phase 1, Gurugram-122002, (Haryana)
Corporate Office: Plot No. B-38, Institutional Area, Sector 32, Gurugram-122001 (Haryana)
E-mail: investor.relations@a2zemail.com, Website: www.a2zgroup.co.in, Tel.: 0124-4517600, Fax: 0124-4380014

Extract of Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2020
(Amount in Rs. Lakhs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
1	Total Income from Operations	2,260.21	6,984.39	11,273.65	38,522.64	7,240.52	13,703.50	16,800.27	69,964.30
2	(Loss)/Profit before exceptional items and tax	(1,011.47)	(4,856.39)	(907.29)	(7,348.20)	(1,291.29)	(5,306.39)	(1,021.49)	(7,618.71)
3	(Loss)/profit before tax	(1,011.47)	(29,237.95)	7,130.54	(25,479.10)	(1,291.29)	(27,626.25)	7,018.34	(23,727.39)
4	(Loss)/profit for the period/year	(1,026.58)	(31,059.66)	7,116.83	(29,088.70)	(1,415.69)	(29,293.05)	6,826.55	(27,814.36)
5	Total Comprehensive Income for the period/year	(998.12)	(31,050.35)	7,109.47	(29,057.63)	(1,387.23)	(29,183.82)	6,819.19	(27,863.39)
6	Equity share capital (Paid-up) Face value of the share - Rs 10/- each)	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99	17,611.99
7	(Loss)/Earnings Per Share (of Rs. 10 each)								
(a)	Basic earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.84	(15.73)
(b)	Diluted earnings per share	(0.58)	(17.64)	4.04	(16.52)	(0.80)	(16.59)	3.63	(15.73)

Note:

- The above Standalone and Consolidated financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and on their recommendation have been approved by the Board of Directors at its meeting held on September 28, 2020.
Basic and diluted earnings per share is not annualized for the quarters ended June 30, 2020, March 31, 2020 and June 30, 2019.
- The above is an extract of detailed format of financial results (Standalone and Consolidated) filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Full format of the quarterly financial results ended June 30, 2020 are available on Company's website at www.a2zgroup.co.in and also be accessed on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

For and on behalf of A2Z Infra Engineering Limited
Sd/-
Rajesh Jain
Whole Time Director & CEO
DIN: 07015927

Place: Gurugram
Date: September 28, 2020

SHRIRAM CITY UNION FINANCE LIMITED
CIN: L28197TN1989PLC02640
Regd. Office: 112, Appasaheb Street, Chennai - 600 001, Telephone No. +91 43 3234 4321
Secretary Office: 114, Sarabhai High Road, Mysore, Chennai - 600 094, Telephone No. +91 43 4302 3200 Fax No. +91 44 4302 3428
Website: www.shriramcityunionfinance.com e-mail: customer.support@shriramcityunionfinance.com Toll Free No. 1800204008

MONEY WHEN YOU NEED IT MOST

Public Notice for change in terms and conditions of acceptance of fixed deposits by the Company with effect from October 1, 2020

In furtherance of the advertisement published by MIS Shriram City Union Finance Limited ("Company") in "Business Standard" and "Makal Kurni" on April 22, 2020 as per the Non-Banking Financial Companies and Miscellaneous Non-Banking Companies (Advertisement) Rules, 1977, it is notified that the following shall be interest rates on acceptance / renewal of fixed deposit effective October 1, 2020 till further notice with all other terms and conditions remaining unchanged.

1. INTEREST RATES-ON FIXED DEPOSITS LESS THAN OR EQUAL TO Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.25	7.30	7.37	7.50	7.25	7.50	5,375
	24	7.44	7.49	7.56	7.70	7.44	8.00	5,600
	36	7.66	7.92	8.00	8.15	7.66	8.64	6,325
	48	7.90	7.96	8.04	8.20	7.90	9.26	6,850
	60	8.09	8.15	8.23	8.40	8.09	9.94	7,485
Applications through online mode Company's web site	15	7.44	7.49	7.56	7.70	7.44	7.78	5,485
	30	7.66	7.92	8.00	8.15	7.66	8.66	6,080
	45	7.90	7.96	8.04	8.20	7.90	9.17	6,720
	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
45	8.13	8.19	8.27	8.45	8.13	9.48	6,775	

2. INTEREST RATES-ON FIXED DEPOSITS GREATER THAN Rs.5 CRORES (w.e.f. OCTOBER 1, 2020)

Particulars	Period (months)	Non-Cumulative Deposits				Cumulative Deposit		
		Monthly % p.a.	Quarterly % p.a.	Half yearly % p.a.	Yearly % p.a.	Rate % (p.a. at Monthly rests)	Effective Yield % p.a.	Maturity value for Rs.5,000/-
Applications through Physical mode	12	7.48	7.53	7.60	7.75	7.48	7.75	5,385
	24	7.67	7.72	7.80	7.95	7.67	8.27	5,625
	36	8.09	8.15	8.23	8.40	8.09	9.13	6,370
	48	8.13	8.19	8.27	8.45	8.13	9.58	6,915
	60	8.32	8.38	8.47	8.65	8.32	10.28	7,570
Applications through online mode Company's web site	15	7.67	7.72	7.80	7.95	7.67	8.03	5,500
	30	8.09	8.15	8.23	8.40	8.09	8.94	6,115
	45	8.13	8.19	8.27	8.45	8.13	9.48	6,775

Additional Interest (for table 1 and 2 above) : 0.40% p

पान १ वरून

बाबरी विध्वंसचा

रुग्णालयात दाखल आहेत. त्यामुळे ते या सुनावणीला हजर राहणार किंवा नाही, हे अद्याप स्पष्ट झाले नाही. बाबरी विध्वंसवेळी कल्याण सिंह उत्तर प्रदेशचे मुख्यमंत्री होते. ते कलम ३१ सप्टेंबरमध्ये या प्रकरणाच्या सुनावणीला हजर राहिले होते. सीबीआयने केलेली सुनावणी या खटल्याची सुनावणी केली आहे. सीबीआयने या प्रकरणात तब्बल ३५१ साक्षीदार व जवळपास ६०० दस्तावेज पुरावा म्हणून सादर केले. याप्रकरणी प्रारंभी एकूण ४८ जणांवर गुन्हा दाखल करण्यात आला होता. पण, यातील १६ जणांचा सुनावणीदरम्यान मृत्यू झाल्याने त्यांचे नाव खटल्यातून वगळण्यात आले. उर्वरित सर्वच आरोपींनी आपल्यावरील आरोप फेटाळून लावले आहेत. माजी उपपंतप्रधान लालकृष्ण अडवाणी यांनी गत २४ जुलै रोजी नोंदवलेल्या आपल्या जबाबदाऱ्यांवर आपल्याला या प्रकरणात राजकीय हेतूने गोवण्यात आल्याचा दावा केला होता. तत्पूर्वी, मुरली मनोहर जोशी यांनीही असाच दावा करत आपण निर्दोष असल्याचे म्हटले होते. कल्याण सिंह यांनी १३ जुलै रोजी आपली साक्ष नोंदवली होती. त्यात त्यांनी तत्कालीन काँग्रेस सरकारने सुड उगवण्यासाठी अडवल्याला या प्रकरणात गोवल्याचा दावा केला होता.

यूपीतील 'निर्भया'चा उपचारादरम्यान मृत्यू

वैद्यकीय महाविद्यालय रुग्णालयात दाखल करण्यात आले होते. सीबीआय तिची प्रकृती नाजूक झाल्याने तिला दिल्लीतील रुग्णालयात हलविण्यात आले. पण जवळपास दोन आठवड्यांपासून जीवमृत्यूची सुड देत असलेल्या तरुणीची मंगळवारी रात्री ३ घंटा नंतरच्या सुमारास प्राणत्याग झालेला. इशान्याद्वारे तिने जबाब नोंदवला. आपल्यावर अत्याचार करणाऱ्या मुन्हेबारांची माहिती देण्यासाठी तिची सुरु असलेली घडपड पाहून पोलीस अधिकाऱ्यांचेही डोळे पाणावले होते. याप्रकरणी अटक करण्यात आलेल्या चार जणांविरुद्ध आता हत्येचा गुन्हाही दाखल करण्यात येणार असल्याचे हायदराचे पोलीस अधीक्षक विजयेंद्र वीर यांनी सांगितले. उत्तर प्रदेश काँग्रेसच्या प्रभारी प्रिंसेंका गांधी, समाजाबादी पक्षाचे अध्यक्ष अखिलेश यादव आणि बसपा प्रमुख मायावती यांनी पीडितेच्या मृत्यूवर दुःख व्यक्त करत, याप्रकरणी योगी सरकारवर सडकून टीका केली आहे. गुपीतील कायदा-सुव्यवस्थेचा बोजवारा उडाल्याची टीका करताना, तीनही नेत्यांनी दोषींविरुद्धात कठोर कारवाई करण्याची मागणी केली आहे. काँग्रेस नेते गजूल यांनी यांनीदेखील दिव्यदरम्यान उत्तरप्रदेशच्या 'वर्ग-विशेष' जंगलराजने आपणही एका तरुणीला मारून टाकल्याची टीका केली आहे. या प्रकरणावरून दिल्लीत काँग्रेस आणि भीम आमिने अडोयलकी केले. देशभरातून या घटनेवर तीव्र संताप व्यक्त करत दोषींना कठोर शासन करण्याची मागणी करण्यात येत आहे.

ऑगस्टमध्ये होऊन गेला १५ पैकी एकाला कोरोना!

सर्वेक्षण केले. त्यात ६.६ टक्के लोकांना कोरोनाचा संसर्ग होऊन गेल्याची लक्षणे आढळली. याशिवाय, ७१ टक्के ग्रॅड व्यक्तीनाही (१८ वर्षांवरील) या विषाणूची लागण झाल्याचे स्पष्ट झाले, अशी माहिती 'आयसीएमआर'चे महासंचालक बलराम भार्गव यांनी मंगळवारी दुसऱ्या सैरी सर्व्हेची आकडेवारी जारी करताना दिली. 'ऑगस्टपर्यंत १० वर्षे व त्याहून अधिक वयाच्या १५ पैकी एकाला कोरोनाची लागण झाली. यात ग्रामीण भागाच्या (४.४ टक्के) तुलनेत शहरी भागातील झोपडपट्टी (१५.६ टक्के) व विंगर झोपडपट्टी भागात (८.२ टक्के) कोरोनाचा संसर्ग अधिक वेगाने होत असल्याचे निष्पन्न झाले, असे ते म्हणाले.

भारत-चीन सीमेवर उस्मानाबाद

जिल्हातील जवान शहीद

पोन महिनांच्या सुट्टीवर टाकली येथे कुटुंबासह आले होते. लॉकडाऊन उठवल्यानंतर त्यांचा कोलावण्यात आल्याने ते परत कर्तव्य बजावण्यासाठी गेले होते. सध्यास्थितीत भारत व चीनदरम्यान सैन्यात चकमक सुरू असून, मेजर वामन पवार हे कर्तव्य बजावत असताना शहीद झाले असल्याची माहिती मंगळवारी (दि.२९) सकाळी ७ वा. टाकली येथील त्यांच्या घरी देण्यात आली आहे. शहीद जवान पवार यांचे पार्थिव त्यांच्या मूळ गावी आणण्यात येणार असून, तेथे शासकीय इतमात अंत्यसंस्कार होणार आहेत.

अजून एका चिनी विषाणूच्या उद्रेकाची शक्यता

शेक्याचा इशारा दिला आहे. त्याचबरोबर याप्रकरणी व्यापक पाठविलेवर याचीची करत, या विषाणूचा वेळेवर वेध घेण्याची गरज वैज्ञानिकांनी व्यक्त केली आहे. देशातील काही ड्रास खोखळीबाबत अतिशय संवेदनशील आहेत. अशा स्थितीत त्यांच्या माध्यमातून लोकांमध्ये याचा प्रादुर्भाव होण्याची भीती एका वैज्ञानिकाने व्यक्त केली आहे. यासंबंधीचे एक संशोधन जून महिन्यात इंडियन जर्नल ऑफ मेडिकल रिसर्चमध्ये देखील प्रकाशित करण्यात आले आहे.

कोरोनाचा 'पीक पॉइंट' येऊन गेला?

कोरोनाच्या सुमारे ६२ लाखोवर रुग्णांची नोंद झाली असून, त्यापैकी ५२ लाखोहून अधिक बरे झाले आहेत. सर्वाधिक रुग्ण असलेल्या महाराष्ट्रातील परिस्थितीत वेगाने सुधारणा होत आहे.

'एचएल'कडून विक्री ३०० वे घूट हेलिकॉप्टर तयार

गवसणी घातली. आपल्या शानदार प्रदर्शनाच्या जोरावर आजूबाजूला हे जास्तिक पातळीवरील एक सर्वोत्कृष्ट हेलीकॉप्टर सिद्ध झाले. एएलएच मार्क-१ ते मार्क-४ हेलीकॉप्टर विकासाचा प्रवास अविचलनशील होता. स्वदेशी डिझाइन आणि विकासातून मजबूती देणारे हे एक माध्यम उदरचालीत माध्यम म्हणाले. एचएल हेलीकॉप्टर विभागात अत्यंतच एक कार्यक्रमात वैमानिक गुणवत्ता महासंस्थानाला याचे अतिरिक्त संचालक (दक्षिण क्षेत्र) वायू, के. जर्मा यांनी हेलीकॉप्टर परिसराचे मुख्य कार्यकारी अधिकारी जी. व्ही. एस. भास्कर यांना ३०० व्हा हेलीकॉप्टरची संशोधित प्रमाणपत्र बहाल केले.

आर्थिक मागास प्रवर्गात मराठ्यांना

आरक्षण नको : संभाजीराजे छत्रपती

खांद्याला खांद्या लावून राहणार आहे. ओबीसी समाजाचा मराठा आरक्षणाला तसेच मराठा समाजाचा ओबीसी आरक्षणाला कोणताच विरोध नाही. उलट दोघांचा एकमेकांना पाठिंब्याच आहे, असेही खा. संभाजीराजे छत्रपती म्हणाले. मराठा आरक्षणासंदर्भात खा. संभाजीराजे छत्रपती यांनी मुख्यमंत्री उद्धव ठाकरे यांची त्यांच्या 'जय' या शासकीय निवासस्थानी भेट घेऊन चर्चा केली. या चर्चेत झालेल्या निर्णयांची त्यांनी नंतर पत्रकारांना माहिती दिली. मराठा समाजाच्या आरक्षणाला सर्वोच्च न्यायालयाने स्थगिती दिली आहे. ही स्थगिती उठवण्यासाठी राज्य सरकारचे प्रयत्न सुरू आहेत. तोपर्यंत मराठा समाजाचा तात्पुरत्या स्वरूपात इंडियनएस म्हणजेच आर्थिक मागासमध्ये समावेश करून १० टक्के आरक्षण देण्याच्या राज्या सरकारच्या विचाराला आमचा विरोध होता, असे सांगून खा. संभाजीराजे छत्रपती म्हणाले. एकतर याबाबतच्या अटी खूपच जाचक आहेत. तसेच मराठा समाजाला आरक्षण मिळवणे म्हणून ४० वर्षांचा लडा सुरू आहे. अनेकांनी त्यासाठी विलंबनही दिले आहे. ते व्यर्थ जाऊ द्यायचे का? तसेच एसबीसी म्हणून मराठा समाजाचा समावेश प्रवेश झालेला आहे. त्याचा जरी तात्पुरता का होईना आर्थिक मागासमध्ये जरी समावेश केला, तर कोणीतरी परत न्यायालयात जाऊन त्याला आरक्षण देऊ शकेल. तर एसबीसीमध्ये आरक्षण मिळवण्यासाठी काळोखीर आडपण निर्माण होऊ शकेल. म्हणूनच याला मराठा समाजाचा विरोध असल्याची याच मुख्यमंत्री उद्धव ठाकरे यांनी निर्दर्शनास आपण आणून दिली. हा निर्णय घेऊ नये, अशी विनंती आपण त्यांना केली. त्यांनाही ती मान्य केली असून, काबाबतचा जोअर निघणार नसल्याचे आश्वासन त्यांनी आपल्या दिल्याचे संभाजीराजे म्हणाले. नोकरभरतीचा विषय आजच्या बैठकीत निघाला नसला, तरी सरकारने मराठा आरक्षणाबाबत स्पष्टीकरण न देता नोकरभरती जाहीर केली, याला आमचा विरोधच असल्याचे ते म्हणाले.

माजीमंत्री एकनाथराव खडसेच्या संभाव्य पक्षांतराची विलप व्हायरल

भाजपाला सोडचिठ्ठी देणार असल्याचा संवाद : खडसेंचा मात्र नकार

जळगाव : गेल्या काही दिवसांपासून माजीमंत्री एकनाथराव खडसे यांच्या पक्षांतराच्या चर्चेला उधान आले असताना आज खडसेंच्या संभाव्य पक्षांतराची विलप व्हायरल झाल्याने एकूण खळबळ उडाली आहे. एकनाथ खडसे हे महिनाभरात पक्ष सोडणार असून दुसऱ्या पक्षात काय पद मिळते, केवळ याची प्रतिक्षा आहे असा संवाद या विलपमध्ये असून ही सोशल मिडीयावर व्हायरल होत आहे. वरणगाव येथील एका कार्यकर्त्यासोबत झालेला हा संवाद असल्याचे सांगण्यात येत आहे. दरम्यान या कॉल बाबत मागील घेण्याची गरज नसल्याचे खडसे यांनी स्पष्ट केले आहे.

अशाच प्रकारे भुसावळ तालुक्यातील वरणगाव येथील भंगाळे नामक कार्यकर्त्यांनी एकनाथ खडसे यांच्याशी संपर्क साधून पक्ष सोडण्याविषयी चर्चा केली. या चर्चेची ऑडिओ क्लिप सोशल मीडियावर व्हायरल झाली आहे. यात या कार्यकर्त्यांनी 'भाज आता राष्ट्रीय कार्यकारणीतही डावलण्यात आल्याने पक्ष सोडा व योग्य निर्णय घ्या' असे म्हटले आहे. तर खडसेंनी कार्यकर्त्याला उत्तर देताना 'हो निर्णय घ्यायचा आहे, दुसरीकडे काय पद मिळते, ते तर बसू दे' दुसरीकडे जाऊन का नुसतेच बसायचे, काही तरी पद मिळते पाहिले की नाही, असे सांगत



महानगरातकार निशय पेटे असे सांगितले.

खेळाडूंचे आमदारांना साकडे अन् एकाच दिवसात क्रीडा संकुल स्वच्छ

अमळनेर : मारवड रस्त्यावर असलेल्या क्रीडा संकुलात झाडे शुद्धपांनी वेढा घालण्याने बुबक, युवती आणि क्रीडा प्रेमींना तेथे प्रवेशही अव्यवहार्य झाला होता. आमदार अनिल पाटील त्या ठिकाणी पाहणी करायला गेले असता खेळाडूंनी त्यांना साकडे घातले आणि समस्याचा पाडा घालला. आमदारांनी पाच-सहा जैशीबी महिलांमार्फत तत्काळ क्रीडा संकुल स्वच्छ केले.



आहेत, पायी फिरणाऱ्यांनाही त्रास होत आहे, तसेच लांब उडी, उंच उडी मैदानावर योग्य माती नाही, संकुलाच्या मैदानात प्रवेश करायला येथील अडथळे आहेत, डबल ब्रार, सिंगल ब्रार नुसलेले आहेत, लाईटची व्यवस्था नाही आदी समस्या मांडल्या. त्यानंतर तत्काळ आ.पाटील यांनी जैशीबी मार्फत तत्काळ करून दिली तसेच मारवड रस्त्यावरील २ किमी पर्यंत झाडे झाडणे काढून रस्ता मोकळा करण्यात आला.

खेळी आ. पाटील यांच्यासह माजी नगराध्यक्ष विनोद पाटील, तालुका क्रीडा समन्वयक सुनील वाघ, क्रीडा संचालनेचे सचिव डी.डी.राजपूत, शिक्षक संचाचे अध्यक्ष संजय पाटील, बरिष्ठ खेळाडू रविंद्र चाचरीया, माजी नगरसेवक विनोद कदम, संधीप चोरपट्टे, पत्रकार किरण पाटील, गणेश भाभरे, महेश माळी, निलेश विसपुते, के.यु.चागुल, व्ही.जी.बोरसे, संजय बोरसे, किशोर मोरे, रोहिदास महाजन, मंडळअधिकारी पी.एस.पाटील, तलाठी गणेश महाजन, धीरज देशमुख, राजेंद्र देशमुख, डी.ए.धनगर, सुशांत पाटील आदी हजर होते.

निभोरासह १४ गावामध्ये माझे कुटुंब माझी जबाबदारी अभियान

निभोरा बु।। ता. रावेर : राज्य शासनाने माझे कुटुंब माझी जबाबदारी हे अभियान गावाबाबत राबवीचे सुरू केले असल्याने निभोरा सह खिडी, खु.खिडी खु. वाघोदा, दसनूर,बलवाडी, सिंगर, पुरी व लोवाडे,भामतवाडी,सिंगाडी, अहिलबाडी, सिंगूर, रेभोटा या १४ गावामध्ये निभोरा आरोग्य केंद्र अंतर्गत हे अभियान सुरू आहे. रावेर तालुका वैद्यकीय अधिकारी डॉ. शिवराव पाटील, निभोरा आरोग्य केंद्र अधिकारी डॉ. पंजन पाटील, डॉ.मोनिषा चौधरी, यांच्या मार्गदर्शनाखाली आरोग्य केंद्र सर्व कर्मचारी तसेच आशा गट प्रवर्तक, सर्व आशा वकर, केंद्र प्रमुख, पर्यवेक्षक, शिक्षक, अंगनवाडी संचिका, मदनोस, स्वयंसेवक नासह सुमारे १२५ जण प्रत्येक गावाबाबत वेगवेगळे पथक करून माझे कुटुंब माझी जबाबदारी हे अभियान घरोघरी जाऊन सर्वोच्च आरोग्य तपासणी करून यशस्वी करीत आहे. एक पथक रोज सुमारे ५० जणांच्या घराला भेटी देत आहे. या दरम्यान शर्मलताण, आनिसपरसत मीटर ने तपासणी करीत असून यात सर्व आनाराची तपासणी करून ज्यांना कोरोना संसर्ग सारखे लक्षण असल्यास त्यांना निभोरा आरोग्य केंद्रात घेऊन तपासणी केली जात आहे .हे अभियान गावात कोरोना संसर्ग होऊ नये व खूप नवे वास्तुची राबविण्यात येत आहे.य अभियानाला सर्वोच्च नुसत प्रतिसाद मिळत आहे.

जाहिर निविदा सुचना

वामा जव्हाण्यांना कळविण्यात येते की, नागरी घनकचरा व्यवस्थापन अंतर्गत खत प्रक्रिया केंद्रासाठी फिट चांगल्या प्रतिका खरेदी करायच्या असल्याने ज्या कोणास पुरवठाकरचे असेल त्यांनी सरदारी निविदा प्रसिद्ध झाले पासून ७ दिवसांच्या आत नगरपालिके कार्यालयाकडे बंद पाकिटात आपले भावपत्रक सादर करावीत मुदती नंतर आलेल्या निविदेचा विचार केला जाणार नाही. निविदा नाकारण्याचा अधिकार खाली सहा करणार यांनी राखून ठेवला आहे.

Advertisement for Kolhapur Municipal Corporation, Kolhapur. City Water Supply & Drainage Division e-Tender Notice No.82 for 2020-21. Includes details about providing, installation and commissioning of various machinery/equipments at Balinga pumping station. Value at Rs.214.38 Lakh. Contact info: www.mahatenders.gov.in

Advertisement for Mahatenders. Services include: 1) Tendering services for various projects. 2) Tendering services for various projects. 3) Tendering services for various projects. Contact: 98200 00000

विद्यापीठांतर्गत अंतिम सत्राच्या परीक्षा पुढे ढकलण्याचा निर्णय

जळगाव : विद्यापीठ व महाविद्यालयीन शिक्षकेतर कर्मचाऱ्यांच्या विविध मागण्यांसाठी सुरु असलेल्या लोखणी बंद ऑनलाइनमुळे उदरचाली परिस्थितीचा विचार करून कवचित्री ब्रिगिगाडची चौकी उतर मध्यराट विद्यापीठाच्या दि.१ आक्टोबर पासून सुरु होण्याची अंतिम चर्चा / अंतिम सत्राच्या सर्व विद्याशाखांच्या परीक्षा पुढे ढकलण्याचा निर्णय परीक्षा व मूल्यमापन मंडळ्याच्या ततडीने झालेल्या बैठकीत मंडळ्याची सार्यांकडी एकमताने घेण्यात आले. अखेर कुलगुरू प्रा. पी.पी.पाटील यांनी सर्व सदस्यांचे मत जाणून घ्यायला घेऊन सत्राच्या पुढील तारखे व नवीन वेळापत्रक ऑनलाइन परिस्थितीत जाहिर केले जाईल, असे सांगितले असल्याची माहिती परीक्षा व मूल्यमापन मंडळ्याचे संचालक बी.पी.पाटील यांनी दिली.

शेतकऱ्यांना हेक्टरी ५० हजार रुपये नुकसान भरपाई द्या संभाजी ब्रिगेडचे तहसिलदारांना निवेदन सादर



ता.काळ विलासा धाया,अन्यथा येत्या काळात संभाजी ब्रिगेड आपल्या स्टार्टअपने तीव्र आंदोलन छेडण्यात येईल असा इशारा ही निवेदनातून देण्यात आलेला आहे. निवेदन देते वेळी संभाजी ब्रिगेडचे जिल्हा प्रचार प्रमुख मनोज महाले, जिल्हा उपाध्यक्ष प्रदीप मायके,जिल्हा सचिव अमोल पाटील, तालुकाध्यक्ष गोपाल पाटील,उपाध्यक्ष प्रदीप भोईटे, सचिव प्रविण पाटील,सहसचिव राम अपार,संधीप पाटील,रिवाज पिंजारी,सुनिल कानडने,सावता सेना जिल्हा युवाध्यक्ष कृष्णा यादव माळी आदी उपस्थित होते.

Advertisement for JVAHARLAL NEHRU PORT TRUST. Includes contact info: 98200 00000, 98200 00000. Website: www.jnport.gov.in

Advertisement for Samarth Sagar. Includes contact info: 98200 00000, 98200 00000. Website: www.samarthsagar.com

Advertisement for Kolhapur Municipal Corporation. Includes details about providing, installation and commissioning of various machinery/equipments at Balinga pumping station. Value at Rs.214.38 Lakh. Contact info: www.mahatenders.gov.in

Advertisement for DEESAN AGRO-TECH PVT. LTD. REQUIREMENT For Growing Edible Oil Compressing Solvent Extraction Plant & Edible Oil Refinery. Includes contact info: 98200 00000, 98200 00000. Website: www.deesan.com

राज्यपालांनी केला वनाधिकार अधिनियमात महत्त्वपूर्ण बदल

मुंबई : राज्यपाल भगतसिंह कोश्यारी यांनी वनाधिकार अधिनियम २००६ मध्ये बदल करीत अनुसूचित जमाती आणि इतर पारंपरिक वननिवासी कुटुंबांना घरे बांधण्यासाठी जमीन उपलब्ध करून देण्याबाबत अधिसूचना जारी केली आहे.

कुटुंबासाठी जागा उपलब्ध नसल्याने इतरत्र स्थलांतर करीत आहेत, वारंवारित सर्व संबंधितांशी चर्चा करून ही अधिसूचना जारी करण्यात आली आहे.

आदिवासींना लगतच्या वनक्षेत्रात घरांसाठी जमीन उपलब्ध होणार

Kolhapur Municipal Corporation, Kolhapur

City Water Supply & Drainage Division e-Tender Notice No.82 for 2020-21 Kolhapur Municipal Corporation invites e-Tender for work of Providing, installation and commissioning and giving satisfactory test and trial of various machinery/equipments at Balinga pumping station Tal.karveer, Dist. Kolhapur in the State of Maharashtra, valued at Rs.214.38 Lakh. Please visit website www.mahatenders.gov.in for detailed information. Date : 29/09/2020

Sd/- Commissioner Kolhapur Municipal Corporation, Kolhapur

भारत सरकार अणुऊर्जा विभाग वांधकाम, सेवा आणि मालमत्ता व्यवस्थापन मध्यवर्ती परिमाण विभाग पूर्वाप्रस्ताव मि ई-निविदा मागणी सूचना

ई-शुद्धिपत्र-१ निमात्र क्र. : डीसीएस/एम/सीएच/सी/एच/सी/बायो/एम-एएस/एनआर/२१/२०२०-२१ दि. १९.०९.२०२० अणुसुरक्षित, मुंबई येथे तापटी इमासाठीच्या मागील बायोगॅस प्लांटचे प्रचालन आणि परिरक्षण कार्य. अंदाजित मूल्य रु. ३८.५० लाख, इतर रु. ७४,०००/-, पूर्व कल्पना कालावधी १२ महिने, निविदा प्रक्रिया शुल्क मूल्य रु. २,२७३/-

महावितरण शुद्धीपत्रक

ई-निविदा क्र.अ.४५/स्वयानियुक्त/कल्याण/वाहन/ई-टी-०६/०७/०८/०९/१०/११/१२/१३/१४/१५/१६/२०२०-२१ ची विजेची कल्प्याची मुल्य वाढ दि.०५.१०.२०२०. पर्यंत निविदा सादर/अपलोड करणाऱ्याची मुल्य दि.०६.१०.२०२० रोजी १३.०० वाजेपर्यंत व निविदा उघडण्याची मुल्य दि.०६.१०.२०२० रोजी १६.०० वाजेपर्यंत अनुक्रमे घडकण्यात आलेली आहे. उर्वरित अटी व शर्तीमध्ये कोणताही बदल करण्यात आलेला नाही. अधिक माहिती आमच्या 'www.etendermahadiscom.in' वा संकेतस्थळावर उपलब्ध आहे.

REQUIREMENT

For Growing Edible Oil Complex Comprising Solvent Extraction Plant & Edible Oil Refinery Commodity Traders Internal Auditor Commercial Officer Sr.Accountant Accountant Computer Operator Flour Mill Operator Flour Mill Helper Safety Officer -Bsc (Chemistry or Physics) with Diploma in Industrial Safety & Health Above vacancy for young dynamic people want to Grow with us; Interested candidates may send their Applications with Bio-data within 7 days to: The Director DEESAN AGRO-TECH PVT. LTD. A-1/2, M.I.D.C., Dhulia - 424 006 (Maharashtra) Phone No.02562-288992, Fax No.239001 E-mail: personnel@deesan.com

TENDER NOTICE MAHA TRANS CO MSETCL invites online bids (E-Tender) from registered contractors agencies on Mahatransco E-Tendering website https://srmetender.mahatransco.in/ for following works.

TENDER NOTICE e-Tender are invited from eligible Registered contractors/Agencies for following works. Tender No. Particulars Tender Amount Price of Tender form EMD (0.5% Tender amount)

महाराष्ट्राच्या बदनामीमागचे सूत्रधार कोण?

मुंबई : सुशांतसिंहच्या क्रिमेयात विवाचा अंश सापडला नाही, असा अहवाल एम्पन्ने दिल्याने राजकीय स्वाध्यासाठी भाजपाने केलेले हीन फावट्यांचे राजकारण उघडपणे पडले आहे. सुशांतसिंहच्या आत्महत्येचे भांडवल करून महाराष्ट्र, मुंबई

सचिन सावंत यांचा सवाल

पोलीस आणि महाराष्ट्राच्या १३ कोटी जनतेची बदनामी करणाना भाजपाचे तोंड या अडवालांमुळे काळे झाले असून भाजपा आणि मोदी सरकारमधील या घडवट्यांमार्फत सूत्रधार कोण आहेत, याचा तपास अजून खोबीआचने करायला, अशी मागणी करिसचे प्रवक्तें सचिन सावंत यांनी केली. सचिन सावंत पुढे म्हणाले की, सुशांतसिंहच्या आत्महत्येला वेगळे बळगण देत त्याचा चापर महाराष्ट्राला बंदनाम करणे, विहारच्या निवडणुकीत व्हाय करणे आणि मोदी सरकारचे सर्व फलवटीकरचे अपयश लपकण्यासाठी केलेल्या भाजपाच्या आटापिटा उघड झाला आहे. अर्धव्यवस्थेची ऐतिहासिक घसरण, प्रचंड भेड्या प्रमाणात वाढलेली खेरीजगारी, कोरोना हाताळण्यात मोदी सरकारला आलेली अपयश, या सर्वांचेरून जनतेचे लक्ष दुसरीकडे वळवण्यासाठी हे घडवटें रचलेले होते. त्याचा पर्दाफाश झालेला आहे.

सर्वोच्च न्यायालय मुंबई येथे तापटी इमासाठीच्या मागील बायोगॅस प्लांटचे प्रचालन आणि परिरक्षण कार्य. अंदाजित मूल्य रु. ३८.५० लाख, इतर रु. ७४,०००/-, पूर्व कल्पना कालावधी १२ महिने, निविदा प्रक्रिया शुल्क मूल्य रु. २,२७३/-

कर्मचारी अनुसूचय टोपे समर्थ सहकारी साखर कारखाना लि. अंजुनाथनवर, पो. अंजुनाथनर ता.अंबड, जि. जालना. फोन: 9623457070 Gmail: samarthnagar@gmail.com

प्रत्यक्ष तांबा सूचना ICICI Home Finance शाखा कार्यालय : अजराजगरीम कॅम्प सि. कार्यालय क्र.२०१-बी, पुणे महारा. पो.ब. १. प्लॉट क्र. -बी१, बाळकृष्ण अडोटी रोड, वराने इ-४/२/२०१२ इ.प्लॉट, ठाणे, महाराष्ट्र-४०० ६०७

जिल्हास्तरावर कृषी न्यायालय स्थापण्याच्या हालचालींना वेग मुंबई : सप्रेम व निकट विवाणे, खते आणि पीक विमा यासंदर्भातील प्रश्नांना शेतकऱ्यांना दरवर्षी सामोरे जावे लागते. यासाठी न्यायाधिकरण तसेच जिल्हास्तरावर कृषी न्यायालय स्थापन करणाऱ्यासंदर्भात महत्त्वपूर्ण चर्चा विधानसभा अध्यक्ष नाना पटोले आणि कृषी मंत्री दशरथ भुसे यांच्या प्रमुख उपस्थितीत झालेल्या बैठकीत करण्यात आली. असे जिल्हास्तरावर कृषी न्यायालय स्थापन करणारे महाराष्ट्र हे देशात पहिले राज्य ठरेल. यामुळे शेतकऱ्यांच्या समस्यांचे निराकरण प्राधान्याने करता येईल, असा विश्वास विधानसभा अध्यक्ष नाना पटोले यांनी व्यक्त केला.

पश्चिम रेल्वे, वांद्रे टर्मिनस-अजमेर आणि उदयपूरदरम्यान त्रि-साप्ताहिक सुपरफास्ट विशेष ट्रेन्स चालविणार आहे

पश्चिम रेल्वे उदयपूर-जयपूर आणि उदयपूर-हरिद्वार जं. दरम्यान ह्याया चित्तोडगड जं. दोन अधिक विशेष ट्रेन्स चालवीत आहेत

E-tender notice (Extension) MAHA TRANS CO MSETCL invites online bids (E-Tender) from registered contractors agencies on Mahatransco E-Tendering website https://srmetender.mahatransco.in/ for following works.

महावितरण ई-निविदा सूचना खातील नमुद केलेल्या कामासाठी अनुभवी सरकारी / निव्वारकारी खात्यात आणि महावितरण कंपनीत नोंदणीकृत असलेल्या केवदांकरांकडून ई-निविदा मागण्यात येत आहेत.

मध्य रेल्वे सामर्थ्यीचे प्राप्ताप निविदा सूचना क्र. ०१/२०२०-२१, DATED : 28.09.2020

WESTERN RAILWAY www.wr.indianrailways.gov.in